TC-MCH 7c structure
|
Common Name | TC-MCH 7c | ||
---|---|---|---|---|
CAS Number | 864756-35-4 | Molecular Weight | 408.46500 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C24H25FN2O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of TC-MCH 7cTC-MCH 7c, a phenylpyridone derivative, is an orally available, selective and brain-penetrable MCH1R antagonist with an IC50 of 5.6 nM for hMCH1R[1]. TC-MCH 7c has Kis of 3.4 nM and 3.0 nM of human and mouse MCH1R, respectively[2]. |
Name | 4-[(4-Fluorobenzyl)oxy]-1-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2( 1H)-pyridinone |
---|
Description | TC-MCH 7c, a phenylpyridone derivative, is an orally available, selective and brain-penetrable MCH1R antagonist with an IC50 of 5.6 nM for hMCH1R[1]. TC-MCH 7c has Kis of 3.4 nM and 3.0 nM of human and mouse MCH1R, respectively[2]. |
---|---|
Related Catalog | |
Target |
IC50: 5.6 nM (hMCH1R)[1] Ki: 3.4 nM (hMCH1R) and 3.0 nM (mouse MCH1R)[1] |
In Vitro | TC-MCH 7c has an IC50 of 9.7 μM for MCH1R in [Ca2+]i mobilization[1]. TC-MCH 7c has IC50s of 23 nM and 9.0 μM for FLIPR and hERG, respectively[2]. |
In Vivo | TC-MCH 7c (oral; 3-30 mg/kg; once-daily for 1.5 months) exhibits excellent body weight reduction in a dose-dependent manner in DIO mice model[1]. TC-MCH 7c (oral; 3-30 mg/kg) with 30 mg/kg has plasma concentrations of 5.1, 1.8, and 0.7 μM at 2, 15, and 24 hours, respectively[2]. Animal Model: C57BL/6J DIO mice[1] Dosage: 3, 10 and 30 mg/kg Administration: Oral; once-daily for 1.5 months Result: Exhibited excellent body weight reduction in a dose-dependent manner. Animal Model: Diet-induced obesity mice[2] Dosage: 3, 10 and 30 mg/kg (Pharmacokinetic Analysis) Administration: Oral Result: Plasma concentrations at 2, 15, and 24 hours were 5.1, 1.8, and 0.7 μM, respectively. |
References |
Molecular Formula | C24H25FN2O3 |
---|---|
Molecular Weight | 408.46500 |
Exact Mass | 408.18500 |
PSA | 43.70000 |
LogP | 3.96810 |